Iron Path Capital-backed VION Biosciences Acquires Aldon Corporation
August 7, 2023
Iron Path Capital has formed VION Biosciences as a life-science roll-up platform and completed the acquisition of Aldon Corporation, a private-label manufacturer and distributor of lab chemicals headquartered in Avon, New York. Aldon will serve as VION’s inaugural platform investment to build a specialty chemicals and reagents business serving biopharma, molecular diagnostics and STEM education markets; Mark Thornton was named CEO of VION Biosciences.
- Buyers
- VION Biosciences, Iron Path Capital
- Targets
- Aldon Corporation
- Platforms
- VION Biosciences
- Industry
- Manufacturing
- Location
- New York, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
VION Biosciences Acquires Ansh Labs
August 29, 2024
Biotechnology
VION Biosciences, the life-science platform backed by Iron Path Capital, has acquired Ansh Labs, an immunoassay development and reagent manufacturer based in Houston, Texas. The add-on expands VION's diagnostics capabilities — adding GMP IVD manufacturing and ISO 13485 certification — and broadens the platform's product and service offerings for clinical diagnostics, research, and pharmaceutical development.
-
VION Biosciences Acquires Echelon Biosciences
August 22, 2024
Biotechnology
VION Biosciences, the life-science platform backed by Iron Path Capital, has acquired Salt Lake City-based Echelon Biosciences, a specialist supplier of lipid-based excipients and lipid nanoparticles. The add-on strengthens VION's capabilities in lipid synthesis and lipid nanoparticle technology to support mRNA and gene-therapy development and advances the platform toward drug manufacturing while keeping Echelon’s leadership and operations intact.
-
VION Biosciences Acquires BioAssay Systems
February 5, 2025
Biotechnology
VION Biosciences acquired Hayward, California–based BioAssay Systems in January 2025 as the fourth add-on for its life‑science products platform. The deal adds BioAssay Systems’ enzymatic and high‑throughput assay kits, reagents and analytical services to VION’s proprietary product portfolio to accelerate capability expansion for drug discovery and life‑science research customers.
-
Lightbeam Health Solutions Acquires Jvion Operating Assets
May 31, 2022
Healthcare Services
Lightbeam Health Solutions has entered into an asset purchase agreement to acquire the operating assets related to Jvion, including its AI-enabled prescriptive analytics and social determinants of health (SDoH) solutions. The acquisition expands Lightbeam's population health management and SDoH capabilities, combining Jvion's clinical intelligence with Lightbeam's analytics and RPM offerings to enhance value-based care for payers and providers.
-
Danaher Acquires Aldevron for $9.6 Billion
June 17, 2021
Biotechnology
Danaher Corporation entered into a definitive agreement to acquire Aldevron from EQT Private Equity for an enterprise value of approximately USD 9.6 billion. Aldevron, headquartered in Fargo, North Dakota with ~600 employees and additional operations in Madison, Wisconsin, will operate as a standalone company within Danaher's Life Sciences segment to expand Danaher's capabilities in genomic medicine and biologics manufacturing.
-
PureTech Scientific (Iron Path Capital) Acquires Glycolic Acid Business from The Chemours Company for $137 Million
June 1, 2023
Manufacturing
PureTech Scientific, a company founded and backed by Iron Path Capital, agreed to acquire The Chemours Company's Glycolic Acid business for $137 million in cash. The transaction (a carve-out/divestiture) closed in August 2023 and creates a standalone platform focused on high‑purity alpha hydroxy acids for life sciences, specialty chemicals and personal care end markets.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.